Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Drug Profile

Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Alternative Names: Contraceptive patch - Johnson & Johnson; Ethinylestradiol/17-deacetyl norgestimate transdermal - Johnson & Johnson; Ethinylestradiol/RWJ 10553; Evra; Evra™; Ortho Evra

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen-Cilag; Ortho-McNeil
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnatrienes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 07 Jan 2021 Gedeon Richter acquires Evra® from Janssen-Cilag
  • 13 Dec 2019 Janssen completes a phase I trial in Healthy volunteers in Belgium, Germany and Netherlands (Transdermal, Patch) (NCT04017195) (EudraCT2019-001893-27)
  • 20 Aug 2019 Janssen initiates a phase I trial in Healthy volunteers in Belgium, Germany and Netherlands (Transdermal, Patch) (NCT04017195)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top